VYVANSE provided behavior, inattention and math test score improvements in children with ADHD

(Porter Novelli) Shire plc, the global specialty biopharmaceutical company, announced results from a 13-hour classroom study in children aged 6 to 12 years with attention deficit hyperactivity disorder, in which researchers found that VYVANSE CII controlled symptoms from the first time measured (1.5 hours) through the last time point assessed (13 hours) post-dose. The study findings were at a national psychiatric meeting in Chicago.


Read more

Related posts

Leave a Reply